Compare Amylx Pharmaceuticals Inc (AMLX) vs Fastly Inc (FSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Fastly Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.87 (market cap $2.64B), while Fastly Inc trades at $29.11 (market cap $4.58B). The key difference: Fastly Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Fastly Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | FSLY | |
|---|---|---|
Market Cap | $2.64B | $4.58B |
Sector | Health | Technology |
52-Week High | $24.19 | $33.50 |
52-Week Low | $7.82 | $6.85 |
Enterprise Value | $2.39B | $4.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Fastly (FSLY) surged 20.86% to $27.75, approaching its consensus price target of $28.25, driven by strong Q2 2026 earnings that beat estimates with $0.15 EPS versus $0.07 expected. Revenue grew 23% year-over-year to $624M in 2025, with improving margins and raised 2026 guidance. Technical indicators show bullish momentum with the stock trading near pivot point resistance at $30, though RSI levels suggest overbought conditions. The company is benefiting from AI-driven demand and security product expansion.
While Fastly shows promising revenue growth and consecutive earnings beats, the stock faces headwinds from negative profitability metrics and cash flow challenges. The net income margin remains negative at -11.8% despite improvement, and the company burned $105.6M in cash during 2025. Analyst sentiment is mixed with 29% buy ratings versus 65% hold, indicating cautious optimism amid execution risks in the competitive edge cloud market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
